Pharmacology and toxicology of the synthetic cannabinoid receptor agonists;Pharmacologie et toxicologie des agonistes synthétiques des récepteurs cannabinoïdes

Reanimation

Volumn 24, Issue 5, 2015, Pages 527-541

  Lovett, C ^a,b   Wood, D M ^a,c   Dargan, P I ^a,c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN HUNTER HOSPITAL   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute toxicity; Psychosis; Spice; Synthetic cannabinoid receptor agonists

Indexed keywords

1 (5 FLUOROPENTYL) 3 (1 NAPHTHOYL)INDOLE; 1 BUTYL 3 (1 NAPHTHOYL)INDOLE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; BENZODIAZEPINE DERIVATIVE; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CLONIDINE; CORTICOSTEROID; DIPHENHYDRAMINE; DRONABINOL; HYDROXYZINE; INFUSION FLUID; LORAZEPAM; METHYLPREDNISOLONE; PLACEBO; PRAMIPEXOLE; PROMETHAZINE; QUETIAPINE; RIMONABANT; SYNTHETIC CANNABINOID RECEPTOR AGONIST; UNCLASSIFIED DRUG; ZOPICLONE;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ACUTE TOXICITY; AGITATION; ARTICLE; BRADYCARDIA; BRAIN ISCHEMIA; CANNABIS ADDICTION; CHRONIC TOXICITY; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); CONFUSION; DELUSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFORMATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; ELIMINATION HALF-LIFE; FAINTNESS; FLUID THERAPY; HALLUCINATION; HEALTH SURVEY; HEART DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; LETHARGY; MAXIMUM PLASMA CONCENTRATION; MOTIVATION; NAUSEA; NEUROPSYCHIATRY; NONHUMAN; OXYGEN THERAPY; PHARMACODYNAMICS; POISON CENTER; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SEMI STRUCTURED INTERVIEW; SMOKING; TACHYCARDIA; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; TOXICOLOGY; UNITED STATES; VERTIGO; VOMITING;

EID: 84942815262     PISSN: 16240693     EISSN: 19516959     Source Type: Journal    
DOI: 10.1007/s13546-015-1104-4     Document Type: Article

References (112)

1. Auwarter V, Kristensen PK, Bartels EM, et al (2009) “Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–7
2. Dargan PI, Wood DM (2013) Novel psychoactive substances. Classification, pharmacology and toxicology. Elsevier Inc, San Diego
3. EMCDDA 2015: European Monitoring Centre for Drugs and Drug Addiction. Perspectives on Drugs–the synthetic cannabinoids. Available at http://www.emcdda.europa.eu/attachements.cfm/att_212361_EN_EMCDDA_POD_2013_Synthetic%20can nabinoids.pdf Last accessed 3rd July 2015
4. Christensen R, Kristensen PK, Bartels EM, et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706–13
5. Dargan PI, Hudson S, Ramsey J, Wood DM (2011) The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in “Spice”. Int J Drug Policy 22: 274–7
6. EMCDDA 2014: EMCDDA-Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA. Available at: http://www.emcdda.europa.eu/attachements.cfm/ att_240380_EN_TDAN15001ENN.pdf Last accessed 3rd July 2015
7. UNODC (2014): United Nations Office on Drugs and Crime. Global Synthetic Drugs Assessment Amphetamine-type stimulants and new psychoactive substances. Available at: https://www. unodc.org/documents/scientific/2014_Global_Synthetic_Drugs_Assessment_web.pdf Last accessed 3rd July 2015
8. UNODC 2011: United Nations Office on Drugs and Crime. Synthetic cannabinoids in herbal products. Available at: https://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf Last accessed 3rd July 2015
9. Brown K (2011) New Zealand bans synthetic cannabinoids BMJ 343:5395
10. Therapeutic Goods Administration 2012. Final decision and reasons for decisions by delegates of the secretary to the department of health and ageing. Commonwealth of Australia. Canberra
11. ACMD 2009: Advisory council on the misuse of drugs 2009. Consideration of the major cannabinoid agonists. Home Office. London
12. ACMD 2012: Advisory Council on the Misuse of Drugs. Further consideration of the synthetic cannabinoids. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119042/synthetic-cannabinoids-2012.pdf Last accessed 3rd July 2015
13. ACMD 2014: Advisory Council on the Misuse of Drugs. Third generation synthetic cannabinoids. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380161/CannabinoidsReport.pdf Last accessed 3rd July 2015
14. Fattore L, Fratta W (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5: 60
15. Hammersley R (2010) Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 105: 373
16. Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Progr Neuro Psychopharm Biol Psych 39: 234–43
17. Zuurman L, Passier PC, de Kam MI, et al (2009) Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol 23: 633–44
18. Martin BR, Wiley JL, Beletskaya I, et al (2006) Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther 318: 1230–9
19. Seely KA, Patton AL, Moran CI, et al (2013) Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. For Sci Int 233: 416–22
20. Hudson S, Ramsey J, King L, et al (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in “herbal high” products. J Anal Toxicol 34: 252–60
21. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108: 534–44
22. Teske J, Weller JP, Fieguth A, et al (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalene-1-yl-(1-pen-tylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878: 2659–63
23. Grigoryev AJ, Kavanagh P, Melnik A (2013) The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl) methanone (AM-694), a high affinity cannabimimetic, by gas chromatography — mass spectrometry. Drug Test Anal 5: 110–5
24. Kneisel S, Teske J, Auwarter V (2014) Analysis of synthetic cannabinoids in abstinence control: long drug detection windows in serum and implications for practitioners. Drug Test Anal 6: 135–6
25. Winstock AR, Barratt MJ (2013) Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 131: 106–11
26. Tofighi B, Lee JD (2012) Internet highs — seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 6: 240–1
27. Barratt MJ, Cakic V, Lenton S (2013) Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 32: 141–6
28. Vandrey R, Dunn KE, Fry JA, Girling ER (2012) A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 120: 238–41
29. Hoyte CO, Jacob J, Monte AA, et al (2012) A characterization of synthetic cannabinoid exposures reported to the national poison data system in 2010. Ann Emerg Med 60: 435–8
30. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL (2014) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanisn underlying greater toxicity? Life Sci 97:45–54
31. Paine MF, Hart HL, Ludington SS, et al (2006) The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34: 880–6
32. Chimalakonda KC, Seely KA, Bratton SM, et al (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Distrib 40: 2174–84
33. Wohlfarth A, Scheidweiler KB, Chen X, et al (2013) Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem 85: 3730–8
34. Chimalakonda KC, Bratton SM, Le VH, et al (2011) Conjugation of synthetic cannabinoids JWH-018 and JWH 073, metabolites by human UDP-glucuronosyltransfers. Drug Metab Dispos 39: 1967–76
35. Grigoryev AJ, Kavanagh P, Melnik A (2012) The detection of the urinary metabolites of 3-[(adamanan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal 4: 519–24
36. Kavanagh P, Grigoryev A, Melnik A, et al (2013) Detection and tentative identification of urinary phase 1 metabolites of phenylacetylindole cannabimimetics JWH-203 and JWH-251, by GC-MS and LC-MS/MS. J Chromatogr V Analyt Technol Biomed Life Sci 934: 102–8
37. Mascia MS, Obinu MC, Ledent C, et al (1999) Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mics. Eur J Pharmacol 383(3):R1–R2
38. Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58: 315–48
39. Matsuda LA, Lolait SJ, Brownstein MJ, et al (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–4
40. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–5
41. Hajos N, Freund TF (2002) Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121: 73–82
42. Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH-018, a common constituent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160: 585–93
43. Atwood BK, Lee D, Straiker J, et al (2011) CP47, 497-C8 and JWH-073 commonly found in “Spice” herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659: 139–45
44. Howlet AC, Barth F, Bonner TI, et al (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161–202
45. Nakajima J, Takahashi M, Seto T, et al (2011) Identification and quantification of two benzoylindoled AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl) methadone, and three cannabimimetic naphthoylindoles JWH-210, JWH 122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 29: 95–110
46. Paronis CA, Nikas SP, Shukla VG, Makriyannis A (2012) Delta(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol 23: 802–5
47. Blunt D (2012) Drug misuse declared: findings from the 2011/12 crime survey for England and Wales 2nd edition
48. Smith K, Flatley J (2011) Drug misuse declared: findings from the 2010/11 British Crime Survey Home Office Statistical Bulletin
49. Pabst A, Piontek D, Kraus L, Muller S (2010) Substance use and substance use disorders results of the 2009 epidemiology survey of substance abuse. Sucht 56: 327–36
50. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE (2013) Monitoring the future national results on drug use: 2012 overview, key findings on adolescent drug use. Institute for Social Research, The University of Michigan, Ann Arbor
51. Werse B, Muller O, Schell C, Morgenstern C (2011) Annual Report “MoSyD”. Drug trends in Frankfurt am Main 2010. Goethe-University Frankfurt am Main, Centre for Drug Research.
52. Hu X, Primack BA, Barnett TE, Cook RL (2011) College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 6: 16
53. Berry-Caban CS, Kleinschmidt PE, Rao DS, Jenkins K (2012) Synthetic cannabinoid and cathinone use among US soldiers. US Army Med Dep J 19–24
54. Monitoring the future: a continuing study of American youth. (online) Available: http://monitoringthefuture.org/ Last accessed 3rd July 2015
55. STUDES 2012: Spanish Observatory on Drugs (2012). Survey on drug use amongst Secondary School Students in Spain. Available at: http://www.pnsd.msc.es/Categoria2/observa/pdf/8_ESTUDES_ 2012_Informe.pdf Last accessed 3rd July 2015
56. Johnson JD, O’Malley PM, Bachman JG, Schulenberg JE (2012) Monitoring the future national survey results on drug use, 1975–2011: vol I, Secondary school students. Institute for Social Research, The University of Michigan, Ann Arbor
57. Winstock A (2011) The 2011 drug surveys. MixMag 238: 50–9
58. Winstock A (2012) MixMag/Global drugs surveys. MixMag 251: 68–73
59. Winstock AR, Barratt MJ (2013) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol Clin Exp 28: 390–3
60. Wood DM, Hunter L, Measham F, Dargan PI (2012) Limited use of novel psychoactive substances in South London nightclubs. QJM 105: 959–64
61. Hestley R, Shelby MK, Crouch DJ, et al (2012) Prevalence of synthetic cannabinoids in US athletes: initial findings. J Anal Toxicol 36: 588–93
62. Kronstrand R, Roman M, Andersson M, Eklund A (2013) Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 37: 534–41
63. Castellanos D, Singh S, Thornton G, et al (2011) Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 49: 347–9
64. Hurst D, Loeffler G, McLay R (2011) Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 168: 1119
65. Werse B, Morgenstern C (2011) Final report-online-survey on ‘legal highs’ (German). Goeth-University Frankfurt am Main, Centre for Drug Research
66. Wood DM, Dargan PI (2012) Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 34: 363–7
67. Forrester MB, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 31: 1006–11
68. Helander A, Beck O, Hagerkvist R, Hulten P (2013) Identification of novel psychoactive drug use in Sweden based on laboratory analysis–initial experiences from the STRIDA project. Scan J Clin Lab Invest 73: 400–6
69. Simmons J, Cookman L, Kang C, Skinner C (2011) Three cases of “spice” exposure. Clin Toxicol 49: 431–3
70. Monte AA, Bronstein AC, Heard KJ, Iwanicki JL (2014) An outbreak of exposure to a novel synthetic cannabinoid. NEJM 370: 389–90
71. Schneir AB, Cullen J, Ly BT (2011) “Spice girls”: Synthetic cannabinoid intoxication. J Emerg Med 40: 296–9
72. Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the Internet. Subst Use Misuse 45: 330–40
73. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108: 534–44
74. Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90: 45–60
75. Harris CR, Brown A (2013) Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 44: 360–6
76. Lapoint J, James LP, Moran CL, et al (2011) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 49: 760–4
77. Freeman MJ, Rose DZ, Myers MA, et al (2013) Ischaemic stroke after use of the synthetic marijuana “spice”. Neurology 81: 2090–3
78. Berson-Leung ME, Yeung LY, Kumar S (2014) Synthetic cannabis and acute ischaemic stroke. J Stroke Cerebrovasc Dis 23: 1239–41
79. Takematsu M, Hoffman RS, Nelson LS, et al (2014). A case of acute cerebral ischaemia following inhalation of a synthetic cannabinoid. Cin Toxicol 52:973–5
80. Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128: 1622–7
81. McKeever RG, Vearrier D, Jacobs D, et al (2015) K2 — not the spice of life — synthetic cannabinoids and ST elevation MI. J Med Toxicol 11: 129–131
82. McQuade D, Hudosn S, Dargan PI, Wood DM (2013) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 69: 373–6
83. Pant S, Deshmukh A, Dholaria B, et al (2012) Spicy Seizure. Am J Med Sci 344: 67–8
84. Bhanushali GK, Jain G, Fatima H, et al (2013) AKI associated with synthetic cannabinoids: a case series. Clin Kidney J 6: 330–3
85. Kazory A, Aiyer R (2013) Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney 6: 330–3
86. Every-Palmer S (2011) Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117: 152–7
87. Faircloth J, Khandheria B (2012) Case report: adverse reaction to synthetic marijuana. Am J Addict 21: 289–90
88. Muller H, Huttner HB, Kohrmann M, et al (2010) Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 42: 152–3
89. Bebarta VS, Ramirez S, Varney SM (2012) Spice: a new “legal” herbal mixture abused by young active duty military personnel. Substance Abuse 33: 191–4
90. Cohen J, Morrison S, Greenberg J, Saidinejad M (2012) Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129:e1064–e7
91. Young AC, Schwarz E, Medina G, et al (2012) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 30: 1320
92. Obafemi AI, Kleinschmidt K, Goto C, Fout D (2015) Cluster of acute toxicity from ingestion of synthetic cannabinoid-laced brownies. J Med Toxicol [in press]
93. Westerbergh J, Hulten P (2011) Novel synthetic cannabinoids, CRA13, JWH-015, JWH-081 and JWH-210 — detected in a case series. Clin Tox 49: 222
94. Drenzek C, Geller RJ, Steck A, et al (2013) Notes from the field: severe illness associated with synthetic cannabinoid use — Brunswick, Georgia. MMWR 62: 939
95. Schwartz MD, Trecki J, Edison LA, et al (2015) A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 48: 573–80
96. Centers for Disease Control and Prevention (CDC) (2012) Acute kidney injury associated with synthetic cannabinoid usemultiple states, 2012. MMWR Morb Mortal Wkly Rep 62: 93–8
97. Thornton SL, Wood C, Friesen MW, Gerona RR (2013) Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol 51: 189–90
98. Buser GL, Gerona RR, Horowitz BZ, et al (2014) Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol 52: 664–73
99. Alhadi S, Tiwari A, Vohra R, et al (2013) High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 9: 199–206
100. Berkowitz EA, Henry TS, Veeraraghavan S, et al (2015) Pulmonary effects of synthetic marijuana: chest radiography and CT findings. AJR 204: 750–7
101. Oluwabusi OO, Lobach L, Akhtar U, et al (2012) Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol 22: 393–5
102. Glue P, Al-Shaqsi S, Hancock D, et al (2013) Hospitalisation associated with use of the synthetic cannabinoid K2. NZ Med J 126: 18–23
103. Ginsburg BC, Schulze DR, Hruba L, McMahon LR (2012) JWH-018 and JWH-073: Delta(9)-tetcahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther 340: 37–45
104. Hruba L, Ginsburg BC, McMahon LR (2012) Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by delta(9)-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther 342: 843–9
105. Nacca N, Vatti D, Sullivan R, et al (2013) The synthetic cannabinoid withdrawal syndrome. J Addict Med 7: 296–8
106. Zimmermann US, Winkelmann PR, Pilhatsch M, et al (2009) Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int 106: 464–7
107. Rominger A, Cumming P, Xiong G, et al (2013) Effects of acute detoxification of the herbal blend “spice gold” on dopamine D receptor availability: A (F)fallypride PET study. Eur Neuropsychopharmacol 23: 1606–10
108. Patton AL, Chimalakonda KC, Moran CL, et al (2013) K2 toxicity: Fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58: 1676–80
109. Bottei E (2014) First report of drug concentrations of the synthetic cannabinoid 5F-PB22 found on post-mortem testing. Clin Toxicol (Phila) 52: 750
110. Behonick G, Shanks KG, Firchau DJ, et al (2014) Four postmortem case reports with quantitative detection of the synthetic cannabinoid 5F-PB22. J Anal Toxicol 38: 559–62
111. Shanks KG, Winston D, Heidingsfelder J, Behonick G (2015) Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int 252: e6–e9
112. Benford DM, Caplan JP (2011) Psychiatric sequelae of Spice, K2, an synthetic cannabinoid receptor agonists. Psychosomatics 52: 295